Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03109470

The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Pope Research Corporation · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require treatment with another biologic medication.

Conditions

Timeline

Start date
2012-11-01
Primary completion
2014-11-01
Completion
2014-11-01
First posted
2017-04-12
Last updated
2017-04-13

Source: ClinicalTrials.gov record NCT03109470. Inclusion in this directory is not an endorsement.